Alnylam Pharmaceuticals
ALNY
#618
Rank
โ‚น2.608 T
Marketcap
โ‚น20,152
Share price
-10.08%
Change (1 day)
59.36%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of December 2024 : โ‚น110.78 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is โ‚น110.78 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2024-12-31โ‚น111.18 B2.31%
2023-12-31โ‚น108.67 B-0.53%
2022-12-31โ‚น109.25 B47.13%
2021-12-31โ‚น74.25 B94.8%
2020-12-31โ‚น38.11 B75.93%
2019-12-31โ‚น21.66 B932.85%
2018-12-31โ‚น2.09 B9.51%
2017-12-31โ‚น1.91 B-81.21%
2016-12-31โ‚น10.19 B
2007-12-31โ‚น0.26 B-34.45%
2006-12-31โ‚น0.40 B21.59%
2005-12-31โ‚น0.33 B6.71%
2004-12-31โ‚น0.31 B268.45%
2003-12-31โ‚น84.64 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
โ‚น44.90 B-59.47%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น231.17 B 108.66%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น114.80 B 3.63%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น43.12 B-61.08%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น23.42 M-99.98%๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น2.671 T 2,311.79%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
โ‚น1.592 T 1,337.70%๐Ÿ‡ซ๐Ÿ‡ท France
โ‚น1.545 T 1,294.93%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel